C., C., J., M., P., C., B., C., J., F., B., G., . . . K., B. (2017). Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials.

C., Cohen, et al. Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz At 48 Weeks in Treatment-naive HIV-1-infected Patients: Pooled Results From the Phase 3 Double-blind Randomized ECHO and THRIVE Trials. 2017.

C., Cohen, et al. Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz At 48 Weeks in Treatment-naive HIV-1-infected Patients: Pooled Results From the Phase 3 Double-blind Randomized ECHO and THRIVE Trials. 2017.